Titan Medical Inc (TITXF) 2.0200 $TITXF
Titan Medical Inc. Announces Receipt of Final Approval to Graduate to TSX
Marketwire - Mon Sep 29, 6:01AM CDT
Titan Medical Inc. ("Titan" or the "Company"
(TSX VENTURE: TMD) (OTCQX: TITXF) today announced that, effective at market opening on September 30, 2014, Titan's common shares and warrants will commence trading on the Toronto Stock Exchange ("TSX" . Concurrent with the TSX listing, the Company's common shares and warrants will be de-listed from the TSX Venture Exchange.
TMD.VN: 2.440 (+0.070)
Titan Medical Inc. Announces the Formation of Its Surgeon Advisory Board
Marketwire - Thu Sep 25, 6:01AM CDT
Titan Medical Inc. ("Titan" or the "Company" (TSX VENTURE: TMD)(OTCQX: TITXF) today announced that it has formed a Surgeon Advisory Board (SAB) that includes seven industry-renowned surgeons who specialize in minimally invasive procedures.
TMD.VN: 2.440 (+0.070)
Titan Medical Inc. Appoints Dr. Dennis Fowler as Executive Vice President, Clinical and Regulatory Affairs
Marketwire - Tue Sep 09, 6:03AM CDT
Titan Medical Inc. ("Titan" or the "Company" (TSX VENTURE: TMD)(OTCQX: TITXF) today announced that Dr. Dennis Fowler, who currently serves as the Company's Director of Clinical Affairs, has been appointed to the newly-created position of Executive Vice President, Clinical and Regulatory Affairs.
TMD.VN: 2.440 (+0.070)
Titan Medical Inc. Announces DTC Eligibility
Marketwire - Wed Sep 03, 6:01AM CDT
Titan Medical Inc. ("Titan" or the "Company" (TSX VENTURE: TMD)(OTCQX: TITXF) announced today that the Depository Trust Company (DTC) has approved the Company's eligibility application for Titan Medical Inc. (CUSIP 88830X108), effective August 21, 2014.
TMD.VN: 2.440 (+0.070)
Titan Medical Inc. Announces Results for the Three and Six Months Ended June 30, 2014
Marketwire - Wed Aug 13, 8:46AM CDT
Titan Medical Inc. ("Titan" or the "Company" (TSX VENTURE: TMD)(OTCQX: TITXF) announced today financial results for the three and six months ended June 30, 2014. All financial results are reported in U.S. dollars, unless otherwise stated.
TMD.VN: 2.440 (+0.070)
With Only One Product to Hope For, the Source of Downside Risks Are Numerous and Diverse; Analyst Report by BrokerBank Securities, Inc.
PR Newswire - Mon Jun 30, 1:30PM CDT
Titan Medical Inc. (OTCQX: TITXF) is a venture company with a market capitalization of about $200 million. Headquartered in Toronto, Canada. The company is involved in building a robotic surgical tool for application in minimally invasive surgery ("MIS" . The key concept of MIS is to minimize the incision area during the surgical operation. In general, MIS leads to quicker recovery, shorter hospital stays, less pain, fewer and smaller scars, reduced risk of infection, and less blood loss.
Titan Medical Inc. Corporate Update
Marketwire Canada - Mon Jun 30, 6:00AM CDT
Titan Medical Inc. (the "Company" (TSX VENTURE:TMD) (OTCQX:TITXF) announced today that Mr. Joe Talarico, Senior Vice President Business Development has resigned his position with the Company. We would like to thank Joe for his contribution to Titan during his four years with the Company. In the interim John Hargrove, Chairman and CEO will assume the responsibilities for Business Development.
TMD.VN: 2.440 (+0.070)
Titan Medical Inc. Retains New York-Based Bertner Advisors, LLC for Investor Relations Services
Marketwire - Wed Jun 18, 1:29AM CDT
Titan Medical Inc. ("Titan" or the "Company" (TSX VENTURE: TMD)(OTCQX: TITXF) announced today that it has retained Bertner Advisors, LLC as its investor relations advisor. Services to be provided in the United States to Titan by Bertner Advisors include counsel on investor relations strategy.
TMD.VN: 2.440 (+0.070)
Titan Medical Inc. Announces Completion of Key Milestone in the Development of Its SPORT(TM) Surgical System
Marketwire - Mon Jun 16, 6:01AM CDT
Titan Medical Inc. (the "Company" (TSX VENTURE: TMD)(OTCQX: TITXF) announced today that it successfully completed animal tissue studies on May 30, 2014, performing a full cholecystectomy (gallbladder removal) procedure using the SPORT Surgical System alpha commercial prototype for the required surgical tasks (including grasping, dissecting, mono-polar cautery and suturing). This comes after the recent successful completion of the Q1 2014 milestone of completing an alpha commercial prototype. "We are most pleased to confirm this key milestone of the successful completion of an actual non-human surgical procedure. The procedure was extensively validated by reviewing video footage of the surgical field and instruments from several viewing angles," said John Hargrove, Titan Medical Chairman and CEO. He further stated, "This is what we expected and targeted for our goals-we have a great team, a great technology and a tremendous opportunity. The development of the SPORT Surgical System remains on schedule."
TMD.VN: 2.440 (+0.070)
Medical Robots Market by Type & Application - Global Forecasts to 2018 for the $1,781 Million Market
M2 - Fri Mar 21, 9:29AM CDT
Research and Markets (http://www.researchandmarkets.com/research/mwj8xd/medical_robots) has announced the addition of the "Medical Robots Market by Type (Surgical Robot, Rehabilitation Robotics, Telemedicine, Assistive Robots, Orthotics, Prosthetics, Radio Surgery, Exoskeleton) & Application (Orthopedic, Neurology, Laparoscopy)- Global Forecasts to 2018" report to their offering. The medical robotics market was valued at $1,781 million in 2013 and is expected to reach $3,764 million by 2018, growing at a CAGR of 16.1% from 2013 to 2018 Over the years, the demand for medical robots has increased significantly. This is due to the paradigm shift in the healthcare industry where emphasis is being laid on minimally invasive surgeries through the use of robots. The global medical robot market is categorized into five broad segments - surgical robots, rehabilitation robots, non-invasive radiosurgery robots, hospital and pharmacy robots, and others. Based on applications, the medical robots market comprises the following segments - neurology, orthopedics, laparoscopy, special education, and other areas. . The hospital and pharmacy robots segment is the fastest-growing segment of the medical robotics market. The increasing demand for telemedicine robots is likely to propel the growth of this market. Along with this, technological developments and increasing adoption of newer technologies by hospitals are some factors that are propelling the demand for hospital and pharmacy robots. The other major segment under hospital and pharmacy robots is the i.v. robots segment. i.v. robots are dispensing robots used in hospitals and pharmacies to accurately compound drug mixtures. These robots are used to administer safe, accurate, efficient, cost-effective, and ready-to-administer IV admixtures. Factors such as an aging population, increasing spending power of the middle-class population, increasing number of private sector hospitals, advancements in endoscopic technologies, and expansions of rural healthcare facilities are also going to play a pivotal role in boosting the demand for medical robotics in the Asian region. China and Japan will be the focal point for the growth of medical robotics in the Asian market. Countries such as Singapore and Thailand are also expected to witness growth in this sector, owing to increasing government support. North America and Europe are both likely to witness an increasing demand for medical robotics owing to technological advancements as well as increased government support in both the geographies. Scope of the Report Segment - Surgical Robots -- Orthopedic Surgical Robots -- Neurological Surgical Systems -- Laparoscopy Robotic Systems -- Steerable Robotic Catheters - Rehabilitation Robots -- Assistive Robots -- Prosthetics -- Orthotics -- Therapeutic Robots -- Exoskeleton Robotic Systems - Non-Invasive Radio surgery Robots - Hospital and Pharmacy Robots -- Telemedicine Robots -- I.V. Robots -- Pharmacy Robots - Others Application - Neurology - Orthopedics - Laparoscopy - Special Education - Others Companies Mentioned - Accuray, Inc. - Hansen Medical, Inc. - Health Robotics S.R.L. - Intuitive Surgical Inc. - Mako Surgical Corp. - Mazor Robotics Ltd. - Medrobotics Corporation - Or Productivity Plc - Renishaw Plc - Titan Medical Inc. For more information visit http://www.researchandmarkets.com/research/mw...cal_robots
ISRG: 491.69 (+13.98), HNSN: 0.99 (+0.02), MZOR: 11.58 (+0.30), ARAY: 7.40 (+0.09)
Titan Medical Inc. Appoints Dr. Bruce Wolff to the Board of Directors
Marketwire - Tue Mar 11, 3:04PM CDT
Titan Medical Inc. ("Titan" or the "Company" (TSX VENTURE: TMD)(OTCQX: TITXF) is pleased to announce that Dr. Bruce Giles Wolff, M. D., Professor of Surgery, Mayo Clinic College of Medicine and Emeritus Chair of the Division of Colon & Rectal Surgery, Mayo Clinic - Rochester, Minn., has been appointed to the Board of Directors. Dr. Wolff has been a member of the Mayo Clinic's Surgical Administrative Committee since 2006. Dr. Wolff is a former President of the American Society of Colon and Rectal Surgeons, a former Director and President of the American Board of Colon and Rectal Surgery, and a former Vice President and Director of the Foundation for Surgical Fellowships. Dr. Wolff has written extensively on colon and rectal surgery issues in almost 300 articles for publications such as The American Journal of Surgery, the Canadian Journal of Surgery, the World Journal of Surgery, Mayo Clinic Proceedings, the America Surgeon, the Journal of Gastrointestinal Surgery, Diseases of the Colon & Rectum, Annals of Surgery and the British Journal of Surgery.
TMD.VN: 2.440 (+0.070)
Titan Medical Inc. Announces Results for Fiscal Year Ended December 31, 2013
Marketwire - Thu Mar 06, 4:54PM CST
Titan Medical Inc. ("Titan" or the "Company" (TSX VENTURE: TMD)(OTCQX: TITXF) announced today its results for the fiscal year ended December 31, 2013.
TMD.VN: 2.440 (+0.070)
Titan Medical Inc. Announces Receipt of Final Approval to Graduate to TSX
Marketwire - Mon Sep 29, 6:01AM CDT
Titan Medical Inc. ("Titan" or the "Company"
(TSX VENTURE: TMD) (OTCQX: TITXF) today announced that, effective at market opening on September 30, 2014, Titan's common shares and warrants will commence trading on the Toronto Stock Exchange ("TSX" . Concurrent with the TSX listing, the Company's common shares and warrants will be de-listed from the TSX Venture Exchange. TMD.VN: 2.440 (+0.070)
Titan Medical Inc. Announces the Formation of Its Surgeon Advisory Board
Marketwire - Thu Sep 25, 6:01AM CDT
Titan Medical Inc. ("Titan" or the "Company"
(TSX VENTURE: TMD)(OTCQX: TITXF) today announced that it has formed a Surgeon Advisory Board (SAB) that includes seven industry-renowned surgeons who specialize in minimally invasive procedures. TMD.VN: 2.440 (+0.070)
Titan Medical Inc. Appoints Dr. Dennis Fowler as Executive Vice President, Clinical and Regulatory Affairs
Marketwire - Tue Sep 09, 6:03AM CDT
Titan Medical Inc. ("Titan" or the "Company"
(TSX VENTURE: TMD)(OTCQX: TITXF) today announced that Dr. Dennis Fowler, who currently serves as the Company's Director of Clinical Affairs, has been appointed to the newly-created position of Executive Vice President, Clinical and Regulatory Affairs. TMD.VN: 2.440 (+0.070)
Titan Medical Inc. Announces DTC Eligibility
Marketwire - Wed Sep 03, 6:01AM CDT
Titan Medical Inc. ("Titan" or the "Company"
(TSX VENTURE: TMD)(OTCQX: TITXF) announced today that the Depository Trust Company (DTC) has approved the Company's eligibility application for Titan Medical Inc. (CUSIP 88830X108), effective August 21, 2014. TMD.VN: 2.440 (+0.070)
Titan Medical Inc. Announces Results for the Three and Six Months Ended June 30, 2014
Marketwire - Wed Aug 13, 8:46AM CDT
Titan Medical Inc. ("Titan" or the "Company"
(TSX VENTURE: TMD)(OTCQX: TITXF) announced today financial results for the three and six months ended June 30, 2014. All financial results are reported in U.S. dollars, unless otherwise stated. TMD.VN: 2.440 (+0.070)
With Only One Product to Hope For, the Source of Downside Risks Are Numerous and Diverse; Analyst Report by BrokerBank Securities, Inc.
PR Newswire - Mon Jun 30, 1:30PM CDT
Titan Medical Inc. (OTCQX: TITXF) is a venture company with a market capitalization of about $200 million. Headquartered in Toronto, Canada. The company is involved in building a robotic surgical tool for application in minimally invasive surgery ("MIS"
. The key concept of MIS is to minimize the incision area during the surgical operation. In general, MIS leads to quicker recovery, shorter hospital stays, less pain, fewer and smaller scars, reduced risk of infection, and less blood loss. Titan Medical Inc. Corporate Update
Marketwire Canada - Mon Jun 30, 6:00AM CDT
Titan Medical Inc. (the "Company"
(TSX VENTURE:TMD) (OTCQX:TITXF) announced today that Mr. Joe Talarico, Senior Vice President Business Development has resigned his position with the Company. We would like to thank Joe for his contribution to Titan during his four years with the Company. In the interim John Hargrove, Chairman and CEO will assume the responsibilities for Business Development. TMD.VN: 2.440 (+0.070)
Titan Medical Inc. Retains New York-Based Bertner Advisors, LLC for Investor Relations Services
Marketwire - Wed Jun 18, 1:29AM CDT
Titan Medical Inc. ("Titan" or the "Company"
(TSX VENTURE: TMD)(OTCQX: TITXF) announced today that it has retained Bertner Advisors, LLC as its investor relations advisor. Services to be provided in the United States to Titan by Bertner Advisors include counsel on investor relations strategy. TMD.VN: 2.440 (+0.070)
Titan Medical Inc. Announces Completion of Key Milestone in the Development of Its SPORT(TM) Surgical System
Marketwire - Mon Jun 16, 6:01AM CDT
Titan Medical Inc. (the "Company"
(TSX VENTURE: TMD)(OTCQX: TITXF) announced today that it successfully completed animal tissue studies on May 30, 2014, performing a full cholecystectomy (gallbladder removal) procedure using the SPORT Surgical System alpha commercial prototype for the required surgical tasks (including grasping, dissecting, mono-polar cautery and suturing). This comes after the recent successful completion of the Q1 2014 milestone of completing an alpha commercial prototype. "We are most pleased to confirm this key milestone of the successful completion of an actual non-human surgical procedure. The procedure was extensively validated by reviewing video footage of the surgical field and instruments from several viewing angles," said John Hargrove, Titan Medical Chairman and CEO. He further stated, "This is what we expected and targeted for our goals-we have a great team, a great technology and a tremendous opportunity. The development of the SPORT Surgical System remains on schedule." TMD.VN: 2.440 (+0.070)
Medical Robots Market by Type & Application - Global Forecasts to 2018 for the $1,781 Million Market
M2 - Fri Mar 21, 9:29AM CDT
Research and Markets (http://www.researchandmarkets.com/research/mwj8xd/medical_robots) has announced the addition of the "Medical Robots Market by Type (Surgical Robot, Rehabilitation Robotics, Telemedicine, Assistive Robots, Orthotics, Prosthetics, Radio Surgery, Exoskeleton) & Application (Orthopedic, Neurology, Laparoscopy)- Global Forecasts to 2018" report to their offering. The medical robotics market was valued at $1,781 million in 2013 and is expected to reach $3,764 million by 2018, growing at a CAGR of 16.1% from 2013 to 2018 Over the years, the demand for medical robots has increased significantly. This is due to the paradigm shift in the healthcare industry where emphasis is being laid on minimally invasive surgeries through the use of robots. The global medical robot market is categorized into five broad segments - surgical robots, rehabilitation robots, non-invasive radiosurgery robots, hospital and pharmacy robots, and others. Based on applications, the medical robots market comprises the following segments - neurology, orthopedics, laparoscopy, special education, and other areas. . The hospital and pharmacy robots segment is the fastest-growing segment of the medical robotics market. The increasing demand for telemedicine robots is likely to propel the growth of this market. Along with this, technological developments and increasing adoption of newer technologies by hospitals are some factors that are propelling the demand for hospital and pharmacy robots. The other major segment under hospital and pharmacy robots is the i.v. robots segment. i.v. robots are dispensing robots used in hospitals and pharmacies to accurately compound drug mixtures. These robots are used to administer safe, accurate, efficient, cost-effective, and ready-to-administer IV admixtures. Factors such as an aging population, increasing spending power of the middle-class population, increasing number of private sector hospitals, advancements in endoscopic technologies, and expansions of rural healthcare facilities are also going to play a pivotal role in boosting the demand for medical robotics in the Asian region. China and Japan will be the focal point for the growth of medical robotics in the Asian market. Countries such as Singapore and Thailand are also expected to witness growth in this sector, owing to increasing government support. North America and Europe are both likely to witness an increasing demand for medical robotics owing to technological advancements as well as increased government support in both the geographies. Scope of the Report Segment - Surgical Robots -- Orthopedic Surgical Robots -- Neurological Surgical Systems -- Laparoscopy Robotic Systems -- Steerable Robotic Catheters - Rehabilitation Robots -- Assistive Robots -- Prosthetics -- Orthotics -- Therapeutic Robots -- Exoskeleton Robotic Systems - Non-Invasive Radio surgery Robots - Hospital and Pharmacy Robots -- Telemedicine Robots -- I.V. Robots -- Pharmacy Robots - Others Application - Neurology - Orthopedics - Laparoscopy - Special Education - Others Companies Mentioned - Accuray, Inc. - Hansen Medical, Inc. - Health Robotics S.R.L. - Intuitive Surgical Inc. - Mako Surgical Corp. - Mazor Robotics Ltd. - Medrobotics Corporation - Or Productivity Plc - Renishaw Plc - Titan Medical Inc. For more information visit http://www.researchandmarkets.com/research/mw...cal_robots
ISRG: 491.69 (+13.98), HNSN: 0.99 (+0.02), MZOR: 11.58 (+0.30), ARAY: 7.40 (+0.09)
Titan Medical Inc. Appoints Dr. Bruce Wolff to the Board of Directors
Marketwire - Tue Mar 11, 3:04PM CDT
Titan Medical Inc. ("Titan" or the "Company"
(TSX VENTURE: TMD)(OTCQX: TITXF) is pleased to announce that Dr. Bruce Giles Wolff, M. D., Professor of Surgery, Mayo Clinic College of Medicine and Emeritus Chair of the Division of Colon & Rectal Surgery, Mayo Clinic - Rochester, Minn., has been appointed to the Board of Directors. Dr. Wolff has been a member of the Mayo Clinic's Surgical Administrative Committee since 2006. Dr. Wolff is a former President of the American Society of Colon and Rectal Surgeons, a former Director and President of the American Board of Colon and Rectal Surgery, and a former Vice President and Director of the Foundation for Surgical Fellowships. Dr. Wolff has written extensively on colon and rectal surgery issues in almost 300 articles for publications such as The American Journal of Surgery, the Canadian Journal of Surgery, the World Journal of Surgery, Mayo Clinic Proceedings, the America Surgeon, the Journal of Gastrointestinal Surgery, Diseases of the Colon & Rectum, Annals of Surgery and the British Journal of Surgery. TMD.VN: 2.440 (+0.070)
Titan Medical Inc. Announces Results for Fiscal Year Ended December 31, 2013
Marketwire - Thu Mar 06, 4:54PM CST
Titan Medical Inc. ("Titan" or the "Company"
(TSX VENTURE: TMD)(OTCQX: TITXF) announced today its results for the fiscal year ended December 31, 2013. TMD.VN: 2.440 (+0.070)
